As of 2025-12-30, the Intrinsic Value of Rocket Pharmaceuticals Inc (RCKT) is -11.13 USD. This RCKT valuation is based on the model Peter Lynch Fair Value. With the current market price of 3.48 USD, the upside of Rocket Pharmaceuticals Inc is -419.85%.
Based on its market price of 3.48 USD and our intrinsic valuation, Rocket Pharmaceuticals Inc (RCKT) is overvalued by 419.85%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -11.13 - -11.13 | -11.13 | -419.85% |
| P/E | (8.10) - (31.88) | (20.09) | -677.3% |
| DDM - Stable | (33.05) - (522.88) | (277.96) | -8087.4% |
| DDM - Multi | (35.34) - (435.30) | (65.40) | -1979.4% |
| Market Cap (mil) | 376.61 |
| Beta | 1.56 |
| Outstanding shares (mil) | 108.22 |
| Enterprise Value (mil) | 321.93 |
| Market risk premium | 4.60% |
| Cost of Equity | 6.55% |
| Cost of Debt | 5.00% |
| WACC | 6.40% |